

Substitute for form 1449B/PTO		ATTORNEY DOCKET NO. 3506.1000-002		APPLICATION NO. 10/757,364	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES February 5, 2008 <small>(Use several sheets if necessary)</small>		FIRST NAMED INVENTOR Steven B. Landau		FILING DATE January 13, 2004	
		EXAMINER Yong Soo Chong	CONFIRMATION NO. 3343		GROUP 1617

U.S. PATENT DOCUMENTS

EXAM -INER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AC7	6,194,382	02-27-2001	Crain, <i>et al.</i>

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

AX5	Wu, Y., <i>et al.</i> , "Effects of Acute and Chronic Administration of MCI-225, a New Selective Noradrenaline Reuptake Inhibitor with 5-HT ₃ Receptor Blocking Action, on Extracellular Noradrenaline Levels in the Hypothalamus of Stressed Rats," <i>Jpn J of Pharmacology</i> , 83, pp. 31-38 (2000).
AY5	Ishigooka, Jr., <i>et al.</i> , "Serotonin-Noradrenaline Reuptake Inhibitors(SNRIs)," <i>Nippon Rinsho</i> , 59, pp. 1523-9, (2001) - Abstract Only.
AZ5	Spiller, R., "Pharmacotherapy: Non-Serotonergic Mechanisms," <i>Gut</i> , 51, Suppl, i87-i90 (2002).

EXAMINER	DATE CONSIDERED
----------	-----------------